Evidence map›Paper›PMID 34310205›Full record

ArticleAntimicrobial agents and chemotherapy2021

Shareef K Shaheen, Praveen R Juvvadi, John Allen, E Keats Shwab, D Christopher Cole, Yohannes G Asfaw, Mili Kapoor, Karen Joy Shaw, William J Steinbach

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026
    Article
  3. New Perspectives on Antimicrobial Agents: Fosmanogepix.Antimicrobial agents and chemotherapy · 2026
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Shareef K ShaheenDivision of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Praveen R JuvvadiDivision of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
John AllenDivision of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
E Keats ShwabDivision of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
D Christopher ColeDivision of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Yohannes G AsfawDivision of Laboratory Animal Resources, Duke University Medical Center, Durham, North Carolina, USA.
Mili KapoorAmplyx Pharmaceuticals, San Diego, California, USA.
Karen Joy ShawHearts Consulting Group, LLC, Poway, California, USA.
William J SteinbachDivision of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Duke Medical Center · USAcademy of Management · USAmplyx Pharmaceuticals (United States) · USDuke University · USDuke University Hospital · US

Funding

Development of non-toxic amphotericin B derivatives targeting invasive fungal infectionsR01AI135812 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI ANDES, DAVID R, BURKE, MARTIN D · 2018 to 2022
$3.7M
Developing a New Therapeutic for the Treatment of Invasive AspergillosisR44AI106235 · NIAID · AMPLYX PHARMACEUTICALS, INC. · PI SHAW, KAREN JOY · 2015 to 2016
$1.5M
Developing a novel antifungal targeting Gwt1 for the treatment of invasive aspergillosis and rare mold infectionsR44AI131864 · NIAID · AMPLYX PHARMACEUTICALS, INC. · PI SHAW, KAREN JOY, STEINBACH, WILLIAM J · 2017 to 2018
$1.5M
Structural Biological Development of Fungal-Specific Calcineurin InhibitorsR56AI112595 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH, HONG, JIYONG · 2020 to 2020
$669k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R44AI106235NIAID NIH HHS R01 AI135812NIAID NIH HHS R44 AI106235NIAID NIH HHS R44 AI131864NIAID NIH HHS R56 AI112595
6 · The paper itself

Abstract

Invasive aspergillosis (IA) due to Aspergillus fumigatus is a deadly infection for which new antifungal therapies are needed. Here, we demonstrate the efficacy of a Gwt1 inhibitor, APX2041, and its prodrug, APX2104, against A. fumigatus. The wild-type, azole-resistant, and echinocandin-resistant A. fumigatus strains were equally susceptible to APX2041

Indexed as

Aspergillus fumigatusProdrugsAnimalsAntifungal AgentsDrug Resistance, FungalIsoxazolesMiceMicrobial Sensitivity TestsAntifungal AgentsIsoxazolesProdrugsAPX001APX001AAPX2041APX2104Aspergillus fumigatusfosmanogepixGwt1invasive aspergillosismanogepixmurine model

Identifiers

PMID34310205
PMCPMC8448089
OpenAlexW3184138977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.